These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8716243)

  • 41. The use of a World Health Organization Transfusion Basic Information Sheet to evaluate transfusion practice in Croatia.
    Skodlar J; Stimac D; Majerić-Kogler V; Doughty H; Sibinga CS
    Vox Sang; 2005 Aug; 89(2):86-91. PubMed ID: 16101689
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Incidence and significance of the bacterial contamination of blood components.
    Blajchman MA
    Dev Biol (Basel); 2002; 108():59-67. PubMed ID: 12220143
    [TBL] [Abstract][Full Text] [Related]  

  • 43. On "Composition, Quality Control, and Labeling of Plasma-Derived Products for the Treatment of von Willebrand disease" (Semin Thromb Hemost 2006;32: 529-536).
    Svae TE; Biesert L; Neisser-Svae A; Kannicht C; Römisch J
    Semin Thromb Hemost; 2007 Mar; 33(2):215-6. PubMed ID: 17340472
    [No Abstract]   [Full Text] [Related]  

  • 44. [Blood transfusion safety].
    Koistinen J
    Duodecim; 2004; 120(7):902-4. PubMed ID: 15154312
    [No Abstract]   [Full Text] [Related]  

  • 45. [Transfusion of blood and blood derivatives. Measurements of safety, circulatory, immunologic and infectious risks and accidents].
    Rouger P; Hergon E
    Rev Prat; 1997 Sep; 47(13):1499-504. PubMed ID: 9339033
    [No Abstract]   [Full Text] [Related]  

  • 46. [The current potentials for optimal whole-blood transfusion and component therapy with blood products--erythrocytes in obstetrics and gynecology--the indications, means and methods].
    Nikolov A; Kovachev I; Gŭrcheva L; Dimitrov A
    Akush Ginekol (Sofiia); 1998; 37(4):46-9. PubMed ID: 10360055
    [No Abstract]   [Full Text] [Related]  

  • 47. [The transfusion law in Germany--an assessment].
    Müller N
    Zentralbl Chir; 2003 Jun; 128(6):459-61. PubMed ID: 12865949
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Acute lung injury after blood transfusion in mechanically ventilated patients.
    Gajic O; Rana R; Mendez JL; Rickman OB; Lymp JF; Hubmayr RD; Moore SB
    Transfusion; 2004 Oct; 44(10):1468-74. PubMed ID: 15383020
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Viral inactivation of cellular blood products].
    Andreu G
    Nouv Rev Fr Hematol (1978); 1993 Jun; 35(3):215-6. PubMed ID: 8337130
    [No Abstract]   [Full Text] [Related]  

  • 50. [Quality assurance in transfusion medicine: organization of a quality assurance system exemplified by the Heidelberg University Blood Bank].
    Stahl D; Kluge A; Roelcke D
    Beitr Infusionsther Transfusionsmed; 1996; 33():247-56. PubMed ID: 8974702
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Risk of cytomegalovirus transmission by blood products to immunocompromised patients and means for reduction.
    Ljungman P
    Br J Haematol; 2004 Apr; 125(2):107-16. PubMed ID: 15059132
    [No Abstract]   [Full Text] [Related]  

  • 52. [The innocuity of stable products derived from human plasma].
    Subtil E
    Contracept Fertil Sex; 1993 Nov; 21(11):836. PubMed ID: 8281234
    [No Abstract]   [Full Text] [Related]  

  • 53. [Indications for the use of blood. A quality assurance project].
    Poulsen LM; Hemmingsen L; Watt-Boolsen S; Skov F
    Ugeskr Laeger; 1995 Oct; 157(42):5864-6. PubMed ID: 7483068
    [No Abstract]   [Full Text] [Related]  

  • 54. [Transfusion of fresh coagulated plasma: products, indications. General methods and recommendations].
    Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS)
    Transfus Clin Biol; 2002; 9(5-6):322-32. PubMed ID: 12555750
    [No Abstract]   [Full Text] [Related]  

  • 55. [Immunosuppresson from transfusion of blood and blood products intumor surgery].
    Bauer M
    Anaesthesist; 2001 Jan; 50 Suppl 1():S16-20. PubMed ID: 11271353
    [No Abstract]   [Full Text] [Related]  

  • 56. Management of complaints in blood establishments: thirteen years of experience at the Croatian Institute of Transfusion Medicine.
    Vuk T; Barišić M; Očić T; Đogić V; Bingulac-Popović J; Sarlija D; Balija M; Jukić I
    Blood Transfus; 2012 Jul; 10(3):302-10. PubMed ID: 22507865
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Plasma Transfusions Prior to Central Line Placement in People with Abnormal Coagulation.
    Bidwell J
    Am J Nurs; 2017 Oct; 117(10):67. PubMed ID: 28957937
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Future trends for provision of safer blood components/blood products.
    Allain JP
    Transfus Sci; 1996 Sep; 17(3):335. PubMed ID: 10163538
    [No Abstract]   [Full Text] [Related]  

  • 59. The potential for bacterial testing of blood products.
    Wagner SJ
    Zentralbl Bakteriol; 1996 Mar; 283(3):253-7. PubMed ID: 8861862
    [No Abstract]   [Full Text] [Related]  

  • 60. US inquiry into HIV in blood products.
    Rowe PM
    Lancet; 1994 Sep; 344(8926):876. PubMed ID: 7916410
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.